This study is currently not recruiting participants.

Single Patient Emergency Use of Spiramycin to Attempt to Prevent Congenital Toxoplasmosis in Unborn Baby

Investigating the Use of Investigational Medication for Toxoplasmosis in Pregnant Women

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

Single patient emergency IND for use of spiramycin in pregnant women infected with toxoplasmosis. The use of spiramycin may prevent transmission of toxoplasmosis to the fetus in utero.

Detailed description of study

Single patient emergency IND for use of spiramycin in pregnant women infected with toxoplasmosis. The use of spiramycin may prevent transmission of toxoplasmosis to the fetus in utero.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: toxoplasmosis
  • Age: 100 years or below
  • Gender: All

This study investigates the use of an investigational medication in pregnant women who are infected with toxoplasmosis. Toxoplasmosis is an infection that can be passed from mother to child during pregnancy, which might cause health issues for the baby.

Participants in this study will receive the investigational medication, which is being studied to see if it can prevent the transmission of toxoplasmosis to the unborn child.

  • Who can participate: Pregnant women diagnosed with toxoplasmosis are eligible to participate. There are no specific age restrictions.
  • Study details: Participants will take spiramycin as directed by the study team. If a placebo is involved, it will be an inactive substance that looks like the investigational medication but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1710878689

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team